Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

475 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. New evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol 8313.
Cox JD, Pajak TF, Marcial VA, Coia L, Mohiuddin M, Fu KK, Selim HM, Byhardt RW, Rubin P, Ortiz HG, et al. Cox JD, et al. Cancer. 1992 Jun 1;69(11):2744-8. doi: 10.1002/1097-0142(19920601)69:11<2744::aid-cncr2820691119>3.0.co;2-u. Cancer. 1992. PMID: 1571904 Clinical Trial.
Comparison of the Radiation Therapy Oncology Group and American Joint Committee on Cancer staging systems among patients with non-small cell lung cancer receiving hyperfractionated radiation therapy. A report of the Radiation Therapy Oncology Group protocol 83-11.
Curran WJ Jr, Cox JD, Azarnia N, Byhardt RW, Shin KH, Emani B, Phillips TL, Selim H, Herskovic A, Mohiuddin M, et al. Curran WJ Jr, et al. Among authors: cox jd. Cancer. 1991 Aug 1;68(3):509-16. doi: 10.1002/1097-0142(19910801)68:3<509::aid-cncr2820680311>3.0.co;2-7. Cancer. 1991. PMID: 1648432 Clinical Trial.
A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.
Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF. Cox JD, et al. J Clin Oncol. 1990 Sep;8(9):1543-55. doi: 10.1200/JCO.1990.8.9.1543. J Clin Oncol. 1990. PMID: 2167952 Clinical Trial.
475 results